Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

• the present invention relates to an improved process for making the compound linezolid.
• Linezolid is a pharmaceutically active compound useful as an antibacterial agent, e.g. for the treatment of diabetic food infections caused by Gram-positive bacteria. It is represented by the formula (I).
• compositions are a sterile isotonic solution for an i.v. infusion, a tablet for oral administration and an aqueous suspension for oral administration. They are marketed, i.e., under brand name ZYVOX by Pfizer.
• linezolid has one asymmetric carbon in the molecule allowing for 2 enantiomers; the marketed compound is the (S)-enantiomer.
• linezolid is present as a free base.
• This amine precursor (II) may be made from various starting materials, e.g.:
• the starting compound (III) may be made from the corresponding tosylate or of general formula (VII) below (WO 2005/099353).
• the starting compound (IV) may be made from the same tosylate or chloride as sub a) (WO2005/099353) or by a cyclization of the oxazolidine ring (WO 99/24393,
• R2 is a chlorophenyl, bromophenyl or 2,4,-dichlorophenyl moiety (WO 2007/1 16284).
• L is a suitable leaving group, for instance a halogen or an alkyl-or aryl sulfonyloxy group,
• the present invention relates to a discovery of an improved process of making linezolid, which is simple in respect to process conditions and provides low amounts of reaction side products.
• the invention provides a process for making the compound 3-(3- fluoro-4-(morpholin-4-yl)phenyl)-2-oxooxazolidin-5(S)-ylmethyl)amine of formula (II) and/or an acid addition salt thereof
• the leaving group is preferably a halo group or an alkyl- or aryl-sulfonyloxy group.
• the compound (II) is converted to linezolid by acetylation, preferably as an acid addition salt and more preferably in water.
• the compound (IXb) is a novel compound and thus represents a specific aspect of the invention.
• the compound (IXa) and/or the compound (IXb) may be used in the making of linezolid.
• the starting material in the process of making linezolid according to the present invention is a compound of general formula (VII)
• L is a leaving group, typically a halo group or an alkyl- or aryl-sulfonyloxy group.
• the "halo” group comprises chloro- or bromo-group, preferably chloro- group.
• the "alkyl” comprises C1-C4 alkyl group and preferably a methyl group.
• the "aryl” comprises phenyl group, which may be optionally substituted by at least one C1-C4 alkyl group, a nitro- group, a hydroxyl group, an C1-C4 alkoxy group, and is preferably p-tolyl or p-nitrophenyl group.
• the compounds are known in the art or may be prepared according to processes known in the art, e.g. from corresponding hydroxyl-methyl compounds of the formula (X).
• the second reaction partner is a metal salt of diformylamide of the formula (VIII).
• the "Me + " is typically sodium or potassium, preferably sodium.
• the compound (VIII) is known in the art and is commonly obtainable by a reaction of the corresponding metal methoxide with formamide, see US5488188 and US5599986. It may be isolated as a solid and stored at ambient conditions.
• the reaction between the compounds (VII) and (VIII) may typically proceed in an inert solvent, which preferably is a polar aprotic solvent, for instance ⁇ , ⁇ -dimethyl formamide, dimethyl sulfoxide , acetonitrile, N-methylpyrrolidone, ⁇ , ⁇ -dimethylacetamide or acetone and mixtures thereof.
• an inert solvent which preferably is a polar aprotic solvent, for instance ⁇ , ⁇ -dimethyl formamide, dimethyl sulfoxide , acetonitrile, N-methylpyrrolidone, ⁇ , ⁇ -dimethylacetamide or acetone and mixtures thereof.
• molar ratio between compound (VII) and compound (VIII) is from 1 :1 to 1 :3, preferably of from about 1:1.1 to about 1 : 1.7.
• the reaction temperature is typically from 50 to 100°C, preferably from 60 to 90°C. At these conditions, the reaction time is about 0.5
• the volatile residues are advantageously removed, e.g. by evaporation, and the residual metal salts are also removed, e.g. by an extraction with water.
• the reaction product comprises a mixture of compounds of formula (IXa) and (IXb).
• both compounds depends on the relative amount of the compound (VIII) in respect to the compound (VII).
• the reaction mixture comprises only the compound (IXa) and/or only the compound (IXb).
• both compounds (IXa) and (IXb) are equally convertible into the amine of the formula (II) in the next step, there is no objective need to separate them or enhance their mutual ratio in the mixture.
• both compounds of the reaction mixture are separated by a suitable separation technique, for instance for analytical purposes.
• the compounds (IXa) and (IXb) may also be obtained in the form of an acid addition salt, e.g. as a hydrochloride, hydrobromide, sulphate, nitrate , phosphate, formate, acetate, propionate, oxalate, malonate, maleate, fumarate, citrate, malate etc.
• any of the compounds (IXa) and (IXb) and/or a mixture thereof is converted, in a next step, into the compound of formula (II) by a mild acid hydrolysis.
• the acid useful for this purpose is a strong mineral or organic acid, for instance hydrochloric acid, sulphuric acid, phosphoric acid,or hydrobromic acid. In general, a molar extent of the acid is used.
• the hydrolysis may proceed in a solvent, which may be water, a lower alcohol (C1-C4 aliphatic alcohol) or a mixture of both.
• Typical reaction temperature is between 0 and 80 °C.
• the course of reaction may be monitored by a suitable analytical technique, e.g. HPLC or TLC.
• the hydrolysis step may be advantageously combined with the preceded step in a one- pot arrangement.
• the product of the reaction comprises the raw amine compound of formula (II). It is formed after the hydrolysis as the corresponding acid addition salt (e.g. hydrochloride or dihydrochloride), which may be optionally neutralized into free amine, if necessary, by a treatment with an equivalent of a base, optionally followed by an extraction.
• the raw compound (II) and/or its acid addition salt, e.g. a hydrochloride or acetate may be, if necessary, purified by known processes and/or isolated in any solid state form , e.g. that as disclosed in US 2006/0258655. Hydrochloride or acetate salt of the compound (II) are the preferred salts.
• Crude or purified amine (II) may be converted to linezolid by a reaction with an acetyl halide or acetic acid anhydride, under conditions known well in the art.
• the acetylation may be performed under conditions of Schotten-Baumann reaction or a modification thereof .
• the name "Schotten-Baumann reaction conditions" indicates the use of an acetylation agent in a presence of a base.
• the acetylation runs in a two-phase solvent system, consisting of water and a water immiscible organic solvent. A base is present within the water phase, which neutralizes the acid generated in the reaction, while the starting materials and product remain in the organic phase.
• a water immiscible organic solvent are toluene, dichloromethane and/or diethyl ether.
• (II) is converted, with or without isolation, into a water soluble acid addition salt of an inorganic acid or acetic acid, e.g. into a hydrochloride, hydrobromide, sulphate, nitrate, phosphate, and/or acetate.
• the salt is dissolved in water, the solution is cooled as close to 0°C as possible, the acetylation agent, preferably acetic anhydride, is added, and the acetylation process is started by continuous addition of a base (preferably an inorganic base, such as sodium carbonate or sodium acetate).
• a base preferably an inorganic base, such as sodium carbonate or sodium acetate.
• the desired linezolid precipitates from the reaction mixture as it is not soluble therein. In this modification, organic solvents are completely avoided.
• the produced linezolid may be isolated in any solid state form known in the art [ Form I (J.Med.Chem. 39(3), 673 (1996)), Form II (WO 01/057035, US 6,559,305), Form III (WO 2005/035530) and many others (WO 2006/004922 , US 2006/0142283), amorphous form (WO 2007/026369) and hydrated forms (US 2006/1 1 1350, EP 20033960 )] and/or may be converted in a suitable acid addition salt.
• the linezolid prepared by the process of the present invention can be formulated and used in pharmaceutical compositions.
• a suitable pharmaceutical composition may comprise linezolid and at least one pharmaceutically acceptable excipient.
• the compositions are useful as antibacterial agents, in treating various diseases caused by some types of bacteria, by administering an effective amount thereof to a patient in need of such treatment. In particular, they are useful in treatment of diabetic food infections caused by Gram-positive bacteria.
• the effective amounts range from 1 mg to 500 mg, expressed as the amount of linezolid base, per day.
• the solid was mixed with 10 ml of methanol an 0.438ml of concentrated hydrochloric acid ( 5.00 mmol) was added.
• the reaction mixture was warmed up in an oil bath to 65°C and stirred at this temperature for 2 hours.
• the mixture was evaporated at diminished pressure and then co-evaporated with toluene ( 60°C, 25 mbar) to yield 220 mg of white glassy solid.
• the reaction mixture was transferred to a 500 ml round bottom flask and cooled down in an ice- water bath.
• Dichoromethane 150 ml was charged to the flask.
• the mixture was vigorously stirred and a solution of NaOH (54.0 g) in water (100 ml) was added, such that the internal temperature did not exceed 20°C.
• the mixture was filtered.
• the filtrate was transfered to a 500 ml separatory funnel and the organic layer was separated. The filter cake was discarded.
• the water layer was extracted with dichloromethane (2 x 50 ml).
• the combined organic layer was dried over Na2S04 (25 g), filtered, and concentrated (60°C, 50 mbar) to provide the product as a tan crystalline solid (18.87 g).

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=42829562

Family Applications (1)

Country Status (3)

Families Citing this family (3)

Citations (2)

Family Cites Families (19)

• 2010
  • 2010-08-11 EP EP10747831.5A patent/EP2603505A1/de not_active Withdrawn
  • 2010-08-11 CN CN2010800692515A patent/CN103140487A/zh active Pending
  • 2010-08-11 WO PCT/EP2010/005209 patent/WO2012019632A1/en active Application Filing
• 2011
  • 2011-07-14 WO PCT/EP2011/062097 patent/WO2012019862A1/en active Application Filing
  • 2011-07-14 CN CN2011800459835A patent/CN103119040A/zh active Pending

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events